Trials / Active Not Recruiting
Active Not RecruitingNCT04101877
The Sahlgrenska Anti-VEGF Study
The Sahlgrenska Anti-VEGF (SAHLVE) Study - a Prospective Randomized Double-blind Comparison of Bevacizumab and Aflibercept in Patients With Neovascular Age-related Macular Degeneration
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 402 (estimated)
- Sponsor
- Vastra Gotaland Region · Other Government
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The study investigates whether patients treated for neovascular (wet) age-related macular degeneration (AMD), with intravitreal injection with bevacizumab (Avastin) after two years need more injections with retained therapy response compared to patients being treated with intravitreal injection with aflibercept (Eylea). The study also aims to evaluate if there is a difference in best-corrected visual acuity, macular thickness, recurrence interval, durability, cost efficiency, as well as vision-related quality of life.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevacizumab Injection | 25 mg/ml |
| DRUG | Aflibercept Injection | 40 mg/ml |
Timeline
- Start date
- 2020-09-03
- Primary completion
- 2026-10-01
- Completion
- 2027-05-01
- First posted
- 2019-09-24
- Last updated
- 2025-11-21
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT04101877. Inclusion in this directory is not an endorsement.